A laboratory technician oversees the filling and packaging testing of large-scale production and distribution of COVID-19 vaccine candidate AZD1222 at the University of Oxford on September 11, 2020 in the line of filling high-performance aseptic vial at Cataland in Anacni, Italy. .Vinchenso Pinto | AFP | Getty Images LONDON – British pharmaceutical company AstraZeneca said on Friday it would begin researching whether it could successfully combine its two corona virus vaccine candidates with Russia’s Kamaleya. Late last month I was asked if I should try to combine two common cold virus based vaccines to increase effectiveness. Russia’s direct investment fund, Russia’s sovereign wealth fund – which funded the development of Spotnik V – will begin its own clinical trials of Astrogeneka’s vaccine by the end of the month. “Being able to combine different COVID-19 vaccines will help improve improved safety and / or vaccine access. This is why it is important to explore different vaccine combinations. Administering immunization programs are more flexible by allowing physicians to make more choices.” Oxford is one of many who are seeking approval from drug regulators amid hopes that a major vaccination campaign could help end the epidemic, with more than 69 million people worldwide infected with the corona virus, more than 1.5 million, to date. Deaths compiled by Johns Hopkins University Data published in the Lancet Medical Journal this week AstraZeneca vaccine averages 70.4% activity Shows that it contains, which is based on the collection of interim data from subsequent clinical trials. The vaccine was also found to be safe and effective. Citing the initial results of the current tests, Russia claims that Sputnik V is more than 90% preventing people from becoming infected with the virus. The state-sponsored scientific research institute could be seen as a vote of confidence in the Spotnik V vaccine in Moscow. In August, Russia became the first country to register a vaccine for emergency use, despite warnings from global authorities about cutting corners. It is now being offered to Russians as part of a mass vaccination campaign. “Astrogeneka’s decision to conduct clinical trials using one of Spotnik V’s two vectors is an important step in combining efforts to increase the effectiveness of its own vaccine against the epidemic,” said Grill Dimitriev, CEO of the Russian Direct Investment Fund. We look forward to the beginning of the collaboration. We look forward to developing and launching this partnership in the future. Shares of AstraZeneca were slightly changed for Friday’s session. Dr. Richard Horton, editor-in-chief of The Lancet, told CNBC on Wednesday that AstraZeneca’s vaccine has a “unique comparative advantage” over other leading candidates. He added that the world could be vaccinated “more effectively” and “much faster” than its counterparts. This is because the estrogen vaccine is considered to be easier to store and distribute than other future corona virus vaccines. . It’s cheaper than the ones developed by Pfizer-Bioendech, Moderna and Johnson & Johnson. AstraZeneca has previously been criticized for some of the methods used in three-phase vaccination trials and for the tested age group. Most of the participants tested in AstraZeneca’s study were under the age of 55, raising questions about whether this vaccine would be effective for the elderly, more than those affected by the infection. The elderly will need further evaluation in a reviewed study released by researchers Wednesday. The AstraZeneca vaccine is a viral vector vaccine based on the weaker version of the common cold virus (adenovirus) that causes infections in chimpanzees. The corona virus, also known as SARS-CoV-2, is designed to attack the corona virus if it later infects the body. The Sputnik V vaccine is based on the human adenovirus vector-based site. .
Source